Skip to contentN
Nika Pharmaceuticals, Inc
N
NIKANika Pharmaceuticals, Inc Q2 2025 · 10-Q
Revenue—
Net Income-$18.38K-$18.38KN/M vs Q2 2024 EPS Diluted$0.00$0.00— vs Q2 2024 Operating Income-$18,381N/M Operating Cash Flowderived-$18,522N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end